One to Watch27 Mar 2025 15:06
From Proactive Investor
'For investors seeking exposure to early-stage biotech, Roquefort presents an intriguing opportunity.
Its relatively modest market valuation reflects the broader challenges facing small-cap life sciences companies, but it may also offer an attractive entry point for those with the stomach to ride the irrational undulations of the UK small-cap sector.
Objectively, the Lyramid transaction is worth way in excess of Roquefort's current worth. So, effectively all the downside has been priced in (and more).
Definitely one to watch.'